ENO1 and myelodysplastic syndrome: Most interestingly, however, was the similarity in ENO1 staining between AML and MDS patients at diagnosis, despite the significant difference in the percentage of blast cells between these cohorts (AML: 50.00, 26.20–72.00% vs. MDS: 9.75, 1.00–21.00%; p = 0.0353; Figure 2F), suggesting that high ENO1 expression was not restricted to the tumour cells.